Lantern Pharma Stock Buy Hold or Sell Recommendation
| LTRN Stock | USD 3.07 0.06 1.92% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Lantern Pharma is 'Cautious Hold'. The recommendation algorithm takes into account all of Lantern Pharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Lantern Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide. In addition, we conduct extensive research on individual companies such as Lantern and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Lantern |
Execute Lantern Pharma Buy or Sell Advice
The Lantern recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lantern Pharma. Macroaxis does not own or have any residual interests in Lantern Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lantern Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Lantern Pharma Trading Alerts and Improvement Suggestions
| Lantern Pharma generated a negative expected return over the last 90 days | |
| Lantern Pharma has high historical volatility and very poor performance | |
| Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lantern Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: LTRN Stock Earnings Lantern Pharma Misses EPS for Q1 2024 - MSN |
Lantern Pharma Returns Distribution Density
The distribution of Lantern Pharma's historical returns is an attempt to chart the uncertainty of Lantern Pharma's future price movements. The chart of the probability distribution of Lantern Pharma daily returns describes the distribution of returns around its average expected value. We use Lantern Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lantern Pharma returns is essential to provide solid investment advice for Lantern Pharma.
| Mean Return | -0.51 | Value At Risk | -6.88 | Potential Upside | 6.07 | Standard Deviation | 4.31 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lantern Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lantern Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Lantern Pharma, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Lantern Pharma back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Perigon Wealth Management, Llc | 2024-09-30 | 28.9 K | Sigma Planning Corp | 2024-09-30 | 28.6 K | Horizon Asset Management Inc/ny | 2024-09-30 | 27.6 K | Bank Of New York Mellon Corp | 2024-06-30 | 26.5 K | Ubs Group Ag | 2024-06-30 | 25.5 K | State Street Corp | 2024-06-30 | 23.7 K | Tocqueville Asset Management L.p. | 2024-09-30 | 17 K | Meridian Wealth Management, Llc | 2024-06-30 | 14.9 K | Northern Trust Corp | 2024-09-30 | 12.8 K | Vanguard Group Inc | 2024-09-30 | 363.7 K | Cm Management, Llc | 2024-09-30 | 185 K |
Lantern Pharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (5.7K) | (16.1K) | (19.5M) | 207.1K | (583.5K) | (612.7K) | |
| Change In Cash | 786.9K | 18.0M | 33.3M | (14.8M) | (15.8M) | (15.0M) | |
| Free Cash Flow | (2.1M) | (5.7M) | (10.6M) | (12.8M) | (14.4M) | (13.6M) | |
| Depreciation | 1.6K | 3.4K | 6.8K | 10.1K | 174.8K | 183.6K | |
| Net Income | (2.4M) | (5.9M) | (12.4M) | (14.3M) | (16.0M) | (15.2M) | |
| End Period Cash Flow | 1.2M | 19.2M | 52.5M | 37.7M | 21.9M | 24.4M | |
| Change To Netincome | 117.8K | 1.2M | 1.2M | 1.7M | 2.0M | 2.1M |
Lantern Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lantern Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lantern Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lantern stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.74 | |
β | Beta against Dow Jones | 1.88 | |
σ | Overall volatility | 4.31 | |
Ir | Information ratio | -0.15 |
Lantern Pharma Volatility Alert
Lantern Pharma exhibits very low volatility with skewness of 0.4 and kurtosis of 1.35. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Lantern Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Lantern Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Lantern Pharma Fundamentals Vs Peers
Comparing Lantern Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lantern Pharma's direct or indirect competition across all of the common fundamentals between Lantern Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lantern Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lantern Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Lantern Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lantern Pharma to competition |
| Fundamentals | Lantern Pharma | Peer Average |
| Return On Equity | -0.45 | -0.31 |
| Return On Asset | -0.28 | -0.14 |
| Current Valuation | 5.45 M | 16.62 B |
| Shares Outstanding | 10.78 M | 571.82 M |
| Shares Owned By Insiders | 14.74 % | 10.09 % |
| Shares Owned By Institutions | 24.10 % | 39.21 % |
| Number Of Shares Shorted | 165.56 K | 4.71 M |
| Price To Book | 1.25 X | 9.51 X |
| EBITDA | (15.79 M) | 3.9 B |
| Net Income | (15.96 M) | 570.98 M |
| Cash And Equivalents | 62.15 M | 2.7 B |
| Cash Per Share | 5.74 X | 5.01 X |
| Total Debt | 234.47 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 12.38 X | 2.16 X |
| Book Value Per Share | 3.82 X | 1.93 K |
| Cash Flow From Operations | (14.35 M) | 971.22 M |
| Short Ratio | 4.74 X | 4.00 X |
| Earnings Per Share | (1.78) X | 3.12 X |
| Target Price | 20.5 | |
| Number Of Employees | 21 | 18.84 K |
| Beta | 1.57 | -0.15 |
| Market Capitalization | 33.76 M | 19.03 B |
| Total Asset | 43.65 M | 29.47 B |
| Retained Earnings | (55.24 M) | 9.33 B |
| Working Capital | 40.66 M | 1.48 B |
| Net Asset | 43.65 M |
Note: Insider Trading [view details]
Lantern Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lantern . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 4328.14 | |||
| Daily Balance Of Power | (0.32) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 3.16 | |||
| Day Typical Price | 3.13 | |||
| Price Action Indicator | (0.12) | |||
| Period Momentum Indicator | (0.06) |
About Lantern Pharma Buy or Sell Advice
When is the right time to buy or sell Lantern Pharma? Buying financial instruments such as Lantern Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lantern Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Trading Thematic Idea Now
Trading
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Trading theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trading Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Lantern Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.